Docetaxel plus prednisone for CRPC patients in mandarin Chinese population: Single Institute Experience

Introduction : Docetaxel (75mg/m 2 three weekly) with prednisone (5mg twice) has been remained one of the standard systemic therapy for CRPC patients. Despite the excellent antitumor effect of docetaxel as well as well tolerance in western CRPC patients, it is important to evaluate the adverse effect of docetaxel based chemotherapy in mandarin Chinese. This study was undertaken to assess the effects of docetaxel in combination with prednisone in mandarin Chinese patients with CRPC. Methods : 17 CRPC patients median age of 71[44-78] were included with 145 cycles of chemotherapy. Treatment consists of intravenous docetaxel 75mg/m 2 three weekly and oral prednisone 5mg twice a day, for maximum ten cycles of therapy. PSA response rate was evaluated with RACIST criteria as well as haematological adverse effects were noted . Results: The total median cycle of chemotherapy given was 10. A PSA response (50% reduction in PSA from baseline) was seen in 66.67% (10 of 15 evaluable patients) at 6 cycles whereas 58.33 % (7 of 12 evaluable patients) at 10 cycles of chemotherapy. The patients that completed 10 cycles were 12(80%). The median PSA value after 10 and 6 cycles were 98.10[0.46-3538] and 46.6 [0.46-954]. With median follow up 13.8 months, OS was19months [95 % CI 15.99-22.05].Hematological adverse events of (any grade) toxicity included neutropenia (26.6%), and febrile neutropenia (6.7%). Conclusions: The effect of docetaxel in combination with prednisone was found effective with manageable adverse effect in Chinese with CRPC. Keywords: castration resistant prostate cancer; docetaxel; PSA; prednisone